Check out your Company Bowl for anonymous work chats.
Sartorius will be admitted to the German DAX blue chip index. After the market closes on September 17, 2021, Sartorius preference shares will be included in the calculation of the DAX, as Deutsche Börse announced on Friday evening. Read more: http://ow.ly/bvro50G4eGS
How can data reduce the timeline for a new drug to reach patients? At Sartorius in Sweden, a growing team of data scientists and software specialists is working on world-leading software solutions for this task. Read more about what drives Andreas Norén and the team at Sartorius Stedim Data Analytics and learn how their software is part of the solution.
A diversity committee, 896 unconscious bias trainings, 100,000 USD donations - the D&I initiatives at Sartorius North America are ongoing. Learn more about what drives Mary Lavin, President, North America, and her team and how Sartorius is taking sustained action within our company and our communities: https://bit.ly/2XK2E4t
Sartorius Stedim Biotech has entered into a partnership with McMaster University to improve manufacturing processes of antibody and virus-based treatments for diseases such as COVID-19, cancers, and genetic disorders.
“When you’re ambitious and passionate, opportunities are everywhere”, says Peter Fu, who joined Sartorius in 2014 and now ensures that production processes at our Chinese customers’ sites run smoothly. Find out how he has built his ideal career alongside the growth of the company and what he thinks is special about Sartorius.
Sartorius acquired cell culture specialist Xell AG headquartered in Bielefeld, Germany. Xell AG develops, produces, and markets media and feed supplements for cell cultures, especially for manufacturing viral vectors that are used in gene therapeutics and vaccines. It has so far been privately owned and employs around 35 people.
Sartorius has continued on its fast growth trajectory, closing the first half of 2021 with significant double-digit increases in both sales revenue and order intake.
Sartorius looks and feels different today than it did one and a half years ago. Over the past decade, the company has grown and changed significantly. Finally in 2020, we launched our sharpended brand, that now revolves around our promise "Simplifying Progress". Since then, the Sartorius Coprorate Branding and Design Team was honored with a series of branding awards for this successful transformation. Read more about the ideas and concepts behind Sartorius brand, along with the latest award wins: https://bit.ly/3r7k7OV
Sartorius announces today that it expects strong first half performance and raises its forecast for the full year of 2021. For the first six months ended June 30, the company expects revenue growth to be approximately 60% in constant currencies with an underlying EBITDA margin slightly above 34.0%.
Sartorius has acquired a majority stake in the reagent manufacturer CellGenix GmbH. The company based in Freiburg, Germany, with around 70 employees produces and markets cell culture components, such as growth factors, cytokines, and media. Sartorius plans to expand the Freiburg site substantially and to establish it as a center of excellence within the group in the areas of development and manufacture of quality critical raw materials for the cell and gene therapy market.
